At MM+M Transform earlier this month, our CMO Alix Hart spoke about techno-empathy and the ways Verily is using technology to prioritize the human experience in healthcare. Watch the recording: https://bit.ly/4d4twOH
Andrew Trister, MD PhD, Verily Chief Medical and Science Officer, discussed with Medtech Insight the opportunity to bring together data from a wide range of sources, including wearables, EHRs and social determinants of health to personalize how we manage health. He highlighted Verily Onduo as a solution for advancing precision health for chronic conditions. Read more: https://bit.ly/3UnIXuk
If we can better understand mental health conditions across time and in a real-world setting, we can inform precise treatments that support patients earlier. Verily’s Andrew Trister, MD PhD and Otsuka Pharmaceutical Companies (U.S.)’s John Kraus shared details on the newly launched longitudinal registry study, ‘My Mental Health Journey,’ which aims to do just that. Read more in Behavioral Health Business: https://bit.ly/3U0uxyU
A huge thank you to all the lab professionals here at Verily! Your behind-the-scenes work and dedication are vital to realizing the promise of precision health. Happy Lab Week!
We welcome our new Chief Revenue Officer Bharat Rajagopal on his first day at Verily! Bharat, who was previously at Microsoft, will be responsible for the strategy and execution of all commercial revenue generating activities to advance precision health. In his own words: “With the recent advances in AI, we have a generational opportunity to discover therapies never imagined before. I’m thrilled to continue my mission at Verily by partnering with organizations across the ecosystem to deliver new data, AI, and technology solutions that accelerate evidence generation and advance precision health.” Learn more: https://bit.ly/3xCtLjU
Are you looking for a new adventure in the Kitchener-Waterloo, Ontario area? We’re hiring for several roles on our rapidly growing engineering teams working on healthcare and life sciences platforms, products and AI. Recently, we launched a longitudinal registry study with Otsuka Pharmaceutical Companies (U.S.) that aims to advance research in depression and mental health. https://bit.ly/43UUiF2 Come build what’s vital! See open positions: https://bit.ly/4asAag3
Verily Onduo is virtual care management for type 2 diabetes (T2D), offering an intuitive mobile app, personalized care plans, dedicated coaching, in-app specialist care (when clinically indicated) and more — all supported by evidence-based outcomes. A 4-month study of Onduo for adults with T2D with intermittent CGM use showed significant glycemic and biomarker improvements, including a 2.4% lower A1C (avg.) in high-risk persons. Read more research insights: https://bit.ly/4cQNxbp Source: J Med Internet Res. 2020 Aug 28;22(8):e21778. doi: 10.2196/21778.
Researchers from Verily, Duke University, and Stanford University demonstrate the potential for use of Verily’s Study Watch to help identify patients at risk for heart failure (HF). The study, published in the Journal of Cardiac Failure, investigates the association of digital walking measures with HF progression. “The study proves that there is more to walking than the number of steps. It shows that participants with subclinical heart failure had lower walking cadence and pace when compared to healthy or at risk individuals,” said Francois Haddad, MD, Clinical Professor of Cardiovascular Medicine at Stanford Medicine. Learn more: https://bit.ly/3vJ7mkt
As leaders in the laboratory science behind wastewater-based epidemiology, Verily Sightline Wastewater offers logistics and surveillance to test for pathogens present in wastewater treatment facilities, allowing for timely monitoring and detection to inform faster public health action. Learn about our work with the Centers for Disease Control and Prevention (CDC) to support the agency’s national wastewater testing program: https://bit.ly/3VPQlQg
